Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial
ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon… - JAMA …, 2019 - jamanetwork.com
Importance Current treatment options for progressive ovarian cancer provide limited benefit,
particularly in patients whose disease has become resistant to platinum-based
chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti–
programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or
refractory ovarian cancer. Design, Setting, and Participants In an expansion cohort of a
phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian …
particularly in patients whose disease has become resistant to platinum-based
chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti–
programmed death-ligand 1 agent, in a cohort of patients with previously treated recurrent or
refractory ovarian cancer. Design, Setting, and Participants In an expansion cohort of a
phase 1b, open-label study (JAVELIN Solid Tumor), 125 patients with advanced ovarian …